PTGX Protagonist Therapeutics Inc.

7.52
+0.09  (+1%)
Previous Close 7.43
Open 7.46
Price To Book 2.14
Market Cap 204,592,481
Shares 27,206,447
Volume 255,622
Short Ratio
Av. Daily Volume 813,340
Stock charts supplied by TradingView

NewsSee all news

  1. Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration

    NEWARK, Calif., Jan. 7, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced the achievement of a research milestone under its worldwide license and research collaboration agreement with

  2. Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis

    NEWARK, Calif., Jan. 6, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that a Phase 2 study of its novel hepcidin mimetic PTG-300 in patients with hereditary hemochromatosis has been

  3. Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia

    NEWARK, Calif., Dec. 3, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced preliminary results from patients with transfusion-dependent (TD) beta-thalassemia in the ongoing TRANSCEND Phase

  4. Protagonist Therapeutics to Present at Two Upcoming Healthcare Investor Conferences

    NEWARK, Calif., Nov. 13, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at two upcoming healthcare

  5. Protagonist Therapeutics Reports Third Quarter 2019 Financial Results

    NEWARK, Calif., Nov. 6, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported its financial results for the third quarter ended September 30, 2019, and provided a corporate update.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b trial discontinued following interim analysis - March 26, 2018. However, company noted August 6, 2018 that human error by CRO contributed to this decision.
PTG-100
Ulcerative colitis
Phase 2 preliminary data released December 3, 2019. Further data due 2020.
PTG-300
Beta-thalassemia
Phase 2 data due 2021.
PTG-200
Crohn's disease
Phase 2 trial to commence 1H 2020.
PN-943
Ulcerative colitis
Phase 2 initiation announced January 6, 2020.
PTG-300
Hereditary hemochromatosis
Phase 2 initiation announced October 30, 2019.
PTG-300
Polycythemia vera

Latest News

  1. Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration

    NEWARK, Calif., Jan. 7, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced the achievement of a research milestone under its worldwide license and research collaboration agreement with

  2. Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis

    NEWARK, Calif., Jan. 6, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that a Phase 2 study of its novel hepcidin mimetic PTG-300 in patients with hereditary hemochromatosis has been

  3. Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia

    NEWARK, Calif., Dec. 3, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced preliminary results from patients with transfusion-dependent (TD) beta-thalassemia in the ongoing TRANSCEND Phase

  4. Protagonist Therapeutics to Present at Two Upcoming Healthcare Investor Conferences

    NEWARK, Calif., Nov. 13, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at two upcoming healthcare

  5. Protagonist Therapeutics Reports Third Quarter 2019 Financial Results

    NEWARK, Calif., Nov. 6, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported its financial results for the third quarter ended September 30, 2019, and provided a corporate update.

  6. Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn's Disease

    NEWARK, Calif., Nov. 6, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that the first patient has been dosed in a Phase 2 study of PTG-200 (also referenced as JNJ-67864238) in patients

  7. Protagonist Therapeutics Secures Debt Facility for up to $50 Million

    NEWARK, Calif., Oct. 31, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced it has entered into a four-year debt facility with MidCap Financial (MidCap), the lead agent, and Silicon Valley

  8. Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera

    NEWARK, Calif., Oct. 30, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that the first patient has been dosed in a Phase 2 study of PTG-300 in patients with polycythemia vera (PV), a

  9. Protagonist Therapeutics Announces Acceptance of Abstracts at the UEG Week 2019 Meeting and the ACG 2019 Annual Scientific Meeting

    NEWARK, Calif., Oct. 1, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that abstracts providing data from the PN-943 and PTG-200 clinical programs have been accepted for poster

  10. Protagonist Therapeutics Reports Granting of Inducement Awards

    NEWARK, Calif., Sept. 4, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on August 30, 2019, it issued inducement awards to two recently hired employees in accordance with their

  11. Protagonist Therapeutics to Present at the H.C. Wainwright & Co. 2019 Annual Healthcare Conference

    NEWARK, Calif., Sept. 3, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the H.C.